Implantation of autologous chondrocytes and matrix autologous chondrocytes are techniques of cartilage repair used in the young adult knee which require harvesting of healthy cartilage and which may cause iatrogenic damage to the joint. This study explores alternative sources of autologous cells.
Chondrocytes obtained from autologous bone-marrow-derived cells and those from the damaged cartilage within the lesion itself are shown to be viable alternatives to harvestderived cells. A sufficient number and quality of cells were obtained by the new techniques and may be suitable for autologous chondrocyte and matrix autologous chondrocyte implantation.
Autologous chondrocyte implantation (ACI)
and matrix autologous chondrocyte implantation (MACI) are now established techniques for the repair of symptomatic isolated lesions of the articular cartilage in the young adult knee. [1] [2] [3] [4] [5] [6] The procedure involves two operative stages. First, the knee is assessed arthroscopically and, if a suitable lesion is identified, a sample of non-injured articular cartilage, approximately 1 cm × 0.5 cm in size, is harvested from a minimally weight-bearing area, usually the femoral margin or trochlear margin. 7 The harvested tissue is enzymatically digested and the liberated chondrocytes are expanded in a monolayer cell culture for a period of four weeks. The cells are recovered from the culture system using trypsinisation techniques. The second stage of the operation involves arthrotomy and direct assessment of the lesion. The area of injury is debrided down to bone and back to a stable rim of tissue. The debrided damaged cartilage from around the defect is discarded. Using the ACI technique, a flap of either periosteum, or a commercially produced collagen, 8 is sutured over the defect and the seal is reinforced with tissue glue. The cultured chondrocytes are then injected beneath it. 5 With the MACI technique, the chondrocytes are preloaded on to a matrix which is then cut to fit the defect.
One concern regarding ACI and MACI is the possible iatrogenic damage caused to unijured healthy articular cartilage during the harvesting procedure. While there are no studies as yet which give confirmed evidence of this iatrogenic damage resulting in a long-term problem in the knee, it is a violation of the normal articular cartilage which presumably has a function. Furthermore, it may take over ten years for any ill-effect of such harvesting to become manifest.
We have examined two alternative sources of cells for chondrocyte implantation which avoid the iatrogenic damage of the harvesting procedure namely, chondrocytes cultured from the debrided discarded tissue obtained from around the articular cartilage lesion itself and those cultured from human autologous stem cells from aspirates from the iliac-crest. Cells from these two sources were compared with cells cultured from the standard harvesting technique.
Patients and Methods
Human chondrocytes from 11 patients undergoing ACI were included in the study. They consented to undergo iliac-crest bone-marrow aspiration for stem cells while under general anaesthesia for their operation. Cells from the injured cartilage around the defect, which are normally discarded, were collected. Three patients had a lesion in the medial femoral condyle, three in the lateral femoral condyle, four had patellar lesions and one a lesion in the trochlear area. Harvested tissue. At the initial arthroscopy, an area of non-injured articular cartilage of 1 cm × 0.5 cm 2 was harvested from a minimally weight-bearing area of the knee using a gouge. The harvested tissue was processed by Research the supply laboratory of Verigen Transplantation Service International (Kastrup, Denmark). The chondrocytes were expanded in a monolayer culture system for a period of four weeks in a medium supplemented by autologous serum. The quantity and viability of the cells were assessed at the supply laboratory using a Trypan Blue exclusion dye test. 9 The cells required for implantation were inserted into the patient's knee at the second operation. Cultured cells surplus to operative requirements were collected and counted. They were placed in a pellet culture at a density of 400 000 cells per pellet by centrifugation at 500 g in 15 ml polypropylene tubes. 10 After removal of the supernatant, cells were cultured at 37˚C with 4% CO 2 in a medium containing Dulbecco's modified Eagle's medium, 11 glucose, ITS+ Premix (Collaborative Biomedical Products, Bedford, Massachusetts), insulin (6.25 µg/ ml), transferrin (6.25 µ/ml), selenious acid (6.25 µg/ml), linoleic acid (5.35 µg/ml; BD Biosciences, Oxford, United Kingdom), bovine serum albumin (1.25 mg/ml), transforming growth factor beta 1 (recombinant human; R&D Systems, Abingdon, United Kingdom), ascorbate, sodium pyruvate (1 mM) and dexamethasone (10 -7 M). The medium was changed every three days. Nine pellets were removed from the culture for analysis on days 7, 14, 21 and 28.
Defect-derived chondrocytes. At the second operation, the lesion was debrided down to bone and back to a stable rim of tissue. The debrided tissue, which is usually discarded, was collected, measured, enzymatically digested with pronase and collagenase and the liberated chondrocytes counted. The cells were then cultured and expanded in a monolayer system identical to that of the conventionally harvested cells in an incubator at 37˚C in a humidified atmosphere of 5% CO 2 . The cell numbers were expanded until a minimum of 15 million cells had been obtained which usually occurred after two passages at confluence. Cells were recovered from the monolayer system by exposure to 0.25% trypsin for five minutes. They were then placed in pellet cultures at 400 000 cells per pellet in an identical medium to that of the harvest-derived cells. Nine pellets were removed from culture for analysis on days 7, 14, 21 and 28. Stem-cell-derived chondrocytes. A bone-marrow aspirate was taken from the posterior iliac crest. The needle was inserted and once it had contacted bone was advanced by rotating it slowly until the cortical bone was penetrated and the marrow cavity entered. Usually, a sudden change in 'give' was noted at this point. The stylet was removed and approximately 5 ml of bone-marrow aspirate was taken into a syringe containing heparin. The marrow aspirate was processed immediately 10, 12 according to the method 13 which has been shown previously to yield mesenchymal stem cells from the aspirate. 14 The aspirate was centrifuged at 180 g for five minutes. The supernatant was extracted and suspended in a medium containing 10% fetal calf serum (Life Technologies, Paisley, United Kingdom), 100 U/ml of penicillin, 100 µg/ml of streptomycin and 0.25 µg/ml of amphotericin and placed in a plastic flask. The cells were cultured in monolayer in a culture medium and conditions identical to those of the harvested and defect-derived cells. The medium was changed every three days. The cell numbers were expanded until a minimum of 15 million cells had been obtained, usually after two passages at confluence. Cells were removed from the monolayer system by exposure to 0.25% trypsin for five minutes and were transferred to a pellet culture system at a density of 400 000 cells per pellet. Nine pellets were taken out of culture for analysis on days 7, 14, 21 and 28. Biochemical analysis. Equivalent sets of pellets from each group were counted and analysed. The 1,9-dimethylmethylene blue (DMB) test 15 was used to assess the content of sulphated glycosaminoglycan (GAG) in the samples. This indicates the presence and quantity of the matrix formed by viable chondrocytes. Cell pellets used for this test were digested at 60˚C for one hour in a 0.5 ml papain digest buffer containing 1 µg/ml of papain (Sigma, Poole, United Kingdom) sodium citrate (55 mM), sodium chloride (150 mM), cysteine hydrochloride (5 mM) and ethylenediamine tetraacetic acid (EDTA) (5 mM; Merck, Poole, United Kingdom). A standard curve was created using chondroitin sulphate A from bovine trachea (Sigma). Cell samples were mixed with 250 µl of DMB and the absorbance at 595 mm was determined using a microplate reader (Bio-Rad Ltd, Hemel Hempstead, United Kingdom). The DNA content, indicating the quantity of nuclei or number of cells present, was assessed using the Hoescht 33258 fluorometric assay (Sigma, Poole, United Kingdom). 16 A standard curve was prepared using DNA from calf thymus (Sigma) and serial dilution techniques. Cell samples were digested in the papain buffer as above then 100 µg/ml of Hoechst (Sigma) at a concentration of 1 µg/ml were added to a 100 µl aliquot of sample and standard. Analysis was performed using a microplate fluorimeter (Fluoroskan Ascent; LabSystems, Oxford, United Kingdom). Histological and immunohistochemical analysis. This was performed on the samples. Pellets were initially dehydrated in 4% paraformaldehyde in 0.1M sodium cacodylate buffer at pH 7.4, then dehydrated by sequential graded alcohol washes followed by xylene and set in paraffin blocks. Sections of 5 µm were stained with Erlichs' 17 haematoxylin and eosin. A semiquantitative streptavidin biotin-immunoperoxidase immunolocalisation technique for type-II collagen was employed using antibodies to collagen type II (CIICI-Developmental Studies Hybridoma Bank, University of Iowa, Iowa). The technique is described in detail by Goldberg et al, 11 and involves rehydration of sections and pretreatment in 0.1% trypsin and 0.1% CaC1 2 in distilled water at 37˚C for ten minutes. Samples were washed and soaked in Tris-buffered saline for ten minutes. Rabbit serum (Dako A/S, Glostrup, Denmark) was added to suppress non-specific binding of IgG. Sections were then incubated with the antibodies to type-II collagen for 30 minutes. The streptavidin-biotin complex (Dako A/S) was then applied for 30 minutes to the samples followed by a solution which contained 0.7 mg/ml-1 of 3,3-diaminobenzidide tetrahydrochloride, 0.7 mg/nl-1 of urea, hydrogen peroxide and Tris buffer 0.06M (Sigma). Samples were washed and mounted.
Results
Debrided injured cartilage. The number of cells obtained before culture from the debrided lesion is shown in Table I . In all cases a sufficient number of viable chondrocytes from the defect-derived tissue was obtained after culture for implantation.
The mean concentration of glycosaminoglycan (GAG) in the cell pellets is shown in Table II . At each time point the pellets containing defect-derived chondrocytes contained a similar concentration of GAG as the harvest-derived chondrocytes. There was no difference in the mean quantity of DNA contained in the two groups of cells (Table III) .
Histologically, no significant difference was seen between the pellets of chondrocytes from the defect and those from harvested cells (Fig. 1) . Immunohistochemical analysis showed a similar positive staining for collagen type II in the chondrocyte pellets derived from the defect in the articular cartilage (Fig. 2) compared with the conventionally harvested cells, indicating that equivalent collagen was produced by the defect-derived cells. Stem cells. It was possible to obtain sufficient stem cells for subsequent ACI and MACI for every patient from a bonemarrow aspirate of 5 ml. When chondrogenesis was induced in these cells and they were compared with harvestderived cells there was no difference in the GAG or chondrocyte DNA detected (Tables IV and V) .
Immunohistochemical analysis demonstrated a similar positive staining for type II-collagen in the pellets of stemcell-derived chondrocytes compared with harvest-derived cells, indicating that equivalent collagen type II was produced by the stem-cell-derived cells.
Chondrocytes obtained from the debrided injured articular cartilage or from autologous bone-marrow aspirate were equivalent to those obtained by harvesting healthy cartilage. For most patients undergoing ACI, the iatrogenic insult to healthy articular cartilage can be avoided by harvesting damaged tissue from around the defect itself or using autologous stem-cell-derived cells.
Discussion
For each set of results analysed biochemically for GAG and DNA, the concentration in the defect-derived cells and the stem-cell-derived cells was at least as good as that obtained from the conventionally harvested cells. On semiquantitative immunohistochemistry, the quantity of type-II collagen was equivalent. This showed that both of the newer methods described above give a sufficient number of chondrocytes for transplantation, allowing the procedure to be performed without damage to healthy tissue to gain a sample of chondrocytes for expansion in culture. The number of passages of cells in the monolayer culture system required to obtain sufficient cells from the defect or from bone-marrowderived cells was not greater that that for the conventionally harvested cells. There is no increased cost for the alternative sources of cells. It is thought that optimal repair of hyaline cartilage occurs when implanted cells mimic the embryological pattern of cartilage formation. 18 It is possible that implanted cultured cells may de-differentiate in the defect of the articular cartilage, then begin the repair process. This would explain why early post-operative biopsies of sites of ACI repair can show immature hyaline cartilage and later more mature adult hyaline cartilage. 19 However, chondrocytes in culture can produce hyaline cartilage and it is reasonable to attempt ACI and MACI of a defect of articular cartilage with cultured chondrocytes. Our study, and that of Chapinyo, Oakes and Van Damme 20 have shown that the injured cartilage from around the defect yields sufficient chondrocytes of equivalent quality to those from uninjured cartilage. The injured hyaline cartilage itself is not capable of self-repair, but contains viable cells capable of differentiating into chondrocytes in culture. If they de-differentiate in the injured tissue, the culture process allows re-differentiation into chondrocytes.
We have shown that sufficient quality chondrocytes can be derived from adult stem cells for use in ACI or MACI and that these are readily available in a large quantity. When reviewing what is already known about the mechanisms of regeneration of articular cartilage, 18, 21 it may be that cells obtained from this source may give the optimal chance of a successful repair. 22 Long-term studies on the clinical outcome of stem-cell repair of lesions of articular cartilage in man have yet to be performed.
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